Bacterial two-component signalling as a therapeutic target in drug design. Inhibition of NRII by the diphenolic methanes (bisphenols).
Domagala
J M
JM
Chemistry Department, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA.
Alessi
D
D
Cummings
M
M
Gracheck
S
S
Huang
L
L
Huband
M
M
Johnson
G
G
Olson
E
E
Shapiro
M
M
Singh
R
R
Song
Y
Y
Van Bogelen
R
R
Vo
D
D
Wold
S
S
D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects*; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors*; D015195:Drug Design; D004352:Drug Resistance, Microbial; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D000071677:Histidine Kinase; D006801:Humans; D015394:Molecular Structure; D051922:PII Nitrogen Regulatory Proteins; D010636:Phenols / Q000737:chemistry* / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004791:Enzyme Inhibitors; D051922:PII Nitrogen Regulatory Proteins; D010636:Phenols; D047428:Protein Kinase Inhibitors; C404143:PIID regulatory protein, Bacteria; D011494:Protein Kinases; D000071677:Histidine Kinase